Karyopharm Therapeutics Inc.
KPTI
$5.40
$0.459.09%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 26.43% | 7.05% | 172.91% | -9.48% | -8.65% |
| Total Depreciation and Amortization | 5.19% | 3.75% | 9.64% | -70.69% | -31.86% |
| Total Amortization of Deferred Charges | 986.18% | 1,074.15% | 631.41% | 3.48% | 3.33% |
| Total Other Non-Cash Items | -265.25% | -108.45% | -1,177.25% | -4.87% | -23.38% |
| Change in Net Operating Assets | -49.95% | 1,808.74% | -685.90% | -202.46% | 218.11% |
| Cash from Operations | -38.88% | 34.12% | -49.81% | -131.23% | 30.76% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -45.07% | 197.25% | 142.14% | 168.34% | 141.11% |
| Cash from Investing | -44.88% | 197.25% | 142.14% | 167.74% | 141.11% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 157.58% | -- | -10.23% | -- | -99.83% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 157.58% | -- | 4,663.49% | -- | -99.83% |
| Foreign Exchange rate Adjustments | -122.47% | 169.23% | 57.69% | 64.44% | -29.37% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -220.23% | 67.95% | 1,554.22% | 57.54% | -86.51% |